Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Justin FerdinandusAnne ZarembaLisa ZimmerLale UmutluRobert SeifertFrancesco BarbatoSelma UgurelEleftheria ChortiViktor GrünwaldKen HerrmannDirk SchadendorfWolfgang Peter FendlerElisabeth LivingstonePublished in: Cancer imaging : the official publication of the International Cancer Imaging Society (2022)
Additional FDG-PET at time of discontinuation of ICB therapy helps identify melanoma patients with a low risk of recurrence and favourable prognosis compared to CT imaging alone. Results may have clinical relevance especially for patients with residual tumor burden.
Keyphrases
- positron emission tomography
- pet ct
- pet imaging
- computed tomography
- end stage renal disease
- high resolution
- chronic kidney disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- magnetic resonance imaging
- contrast enhanced
- magnetic resonance
- fluorescence imaging
- photodynamic therapy
- bone marrow
- cell therapy
- free survival
- basal cell carcinoma